Prognostic value of uPA and p53 accumulation measured by quantitative biochemical assays in 1245 primary breast cancer patients: A multicentre study

British Journal of Cancer

Volumn 80, Issue 3-4, 1999, Pages 536-545

  Broet P ^a   Spyratos, F ^b   Romain, S ^c   Quillien, V ^d   Daver, A ^e   Ricolleau, G ^f   Rallet, A ^g   Toulas, C ^h   Asselain, B ^a  

^a INSTITUT CURIE   (France)

^b CENTRE RENÉ HUGUENIN   (France)

^c CHRU   (France)

^d CENTRE EUGÈNE MARQUIS   (France)

^e CENTRE PAUL PAPIN   (France)

^f CENTRE RENÉ GAUDUCHEAU   (France)

^g Institut Godinot   (France)

^h INSTITUT CLAUDIUS REGAUD   (France)

Author keywords

Breast cancer; Luminometric immunoassay; p53; Survival analysis; Urokinase plasminogen activator

Indexed keywords

ESTROGEN RECEPTOR; PROTEIN P53; UROKINASE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER SURVIVAL; CLINICAL TRIAL; CYTOSOL; FEMALE; FOLLOW UP; FRANCE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOASSAY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPH NODES; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; URINARY PLASMINOGEN ACTIVATOR;

EID: 0032938496     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690389     Document Type: Article

References (42)

1. Akaike H (1974) A new look at the statistical model identification. IEEE Transactions on Automatic Control 19: 716-723
2. Allred DC, Clark GM, Elledge R, Fuqua SA, Brown RW, Chamness GC, Osborne CK and McGuire WL (1993) Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 85: 200-206
3. Altman DG (1991) Categorising continuous variables. Br J Cancer 64: 975
4. Altman DG, Lausen B, Sauerbrei W and Schumacher M (1994) Dangers of using 'optimal' cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 86: 829-835
5. Andreasen PA, Kioller L, Christensen L and Duffy MJ (1997) The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 72: 1-22
6. Banks L, Matlashewski G and Crawford L (1986) Isolation of human p53 specific monoclonal antibodies and their use in the studies of human p53 expression. Eur J Biochem 159: 529-534
7. Berns EMJJ, De Witte HH, Klinj JGM, Willman K, Look MP, Meijer-van Gelder ME, Benraad T and Foekens J (1997) Prognostic value of TP53 protein accumulation in human primary breast cancer: an analysis by luminometric immunoassay on 1491 tumor cytosols. Anticancer Res 17: 3003-3006
8. Bloom HJ and Richardson WW (1957) Histological grading and prognosis in breast cancer. Br J Cancer 11: 359-377
9. Borg A, Lennersand J, Stenmark-Askmalm M, Fernö M, Brisfors A, Öhrvik A Stål O, Killander D, Lane D and Brundell J (1995) Prognostic significance of p53 overexpression in primary breast cancer; a novel luminometric immunoassay applicable on steroid receptor cytosols. Br J Cancer 71: 1013-1017
10. Bouchet C, Spyratos F, Martin PM, Hacène K, Gentile A and Oglobine J (1994) Prognostic value of urokinase activator and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinoma. Br J Cancer 69: 398-405
11. Bouchet C, Spyratos F, Hacène K, Durcos L, Bécette V and Oglobine J (1998) Prognostic value of urokinase activator in primary breast carcinoma: comparison of two immunoassay methods. Br J Cancer 77: 1495-1501
12. Cox DR (1972) Regression models and life tables (with discussion). J R Stat Soc B 34: 187-202
13. De Witte HH, Foekens JA, Lennerstrand J, Smid M, Look MP, Klijn GM, Benraad TJ and Berns MJJ (1996) Prognostic significance of tp53 accumulation in human primary breast cancer: comparison between a rapid quantitative immunoassay and SSCP analysis. Int J Cancer 69: 125-130
14. Duffy MJ (1996) Proteases as prognostic markers in cancer. Clin Cancer Res 2: 613-618
15. Elledge RM (1996) Assessing p53 status in breast cancer prognosis; where should you put the thermometer if you think your p53 is sick? J Natl Cancer Inst 88: 141-142
16. Elledge RM, Clark GM, Fuqua SAW and Yu YY (1994) Allred C: p53 protein accumulation detected by five different antibodies: relationship to prognosis and heat shock protein 70 in breast cancer. Cancer Res 54: 3752-3757
17. EORTC (European Organization for Research and Treatment of Cancer) (1980) Breast cancer cooperative group. Revision of the standards for the assessment of hormone receptors in human breast cancer. Eur J Cancer 16: 1513-1515
18. Falette N, Paperin Mp, Treilleux I, Gratadour AC, Peloux N, Mignote H, Tooke N, Lofman E, Iganas M, Brémond A, Ozturk M and Puisìeux A (1998) Prognostic value of p53 gene mutations in a large series of node-negative breast cancer patients. Cancer Res 58: 1451-1456
19. Fernö M, Bendahl, P.O, Borg A, Brundell J, Hirschberg L, Olsson H and Killander D (1996) Urokinase plasminogen activator, a strong independent prognostic factor in breast cancer, analysed in steroid receptor cytosols with luminometric immunoassay. Eur J Cancer 5: 793-801
20. Figueroa JA, Yee D and McGuire WL (1993) Prognostic indicators in early breast cancer. Am J Med Sci 305: 176-182
21. Fockens JA, Schmitt M, Van Putten WLJ, Peters HA, Bontenbal M, Jänicke F and Klijn JGM (1992) Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer. Cancer Res 52: 6101-6105
22. Foekens JA, Schmitt M, Van Putten WLJ, Peters HA, Kramer MD, Jäunicke F and Klijn JGM (1994) Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol 12: 1648-1658
23. Gottlieb TM and Oren M (1996) p53 in growth control and neoplasia. Biochem Biophys Acta 1287, 77-102
24. Jänicke F, Schmitt M, Pache L, Harbeck N, Höfler H and Graeff H (1993) Urokinase (uPA) and its inhibitor PA1-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat 24: 195-208
25. Jänicke F, Pache L, Schmitt M, Ulm K, Thomssen C, Prechtl A and Graeff H (1994a) Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor plasminogen activator inhibitor-type 1. Cancer Res 54: 2527-2530
26. Jänicke F, Thomssen C, Pache M, Schmitt M and Graeff H (1994b) Urokinase (uPA) and PAI-1 as selection criteria for adjuvant chemotherapy in axillary node-negative breast cancer patients. In Prospects in Diagnosis and Treatment of Breast Cancer, Schmitt M, Graeff H and Kendermann G (eds) pp. 207-218. Excerpta Medica: Amsterdam
27. Kaplan EL and Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481
28. Knoop A, Andreasen PA, Andreasen JA, Hansen S, Laenkholm AV, Simonsen ACW, Andersen J, Overgaard J and Rose C (1998) Prognostic significance of urokinase-type plasminogen activator and type plasminogen activator inhibitor-1 in primary breast cancer. Br J Cancer 77: 932-940
29. MacGrogan G, Bonichon F, de Mascarel I, Trojani M, Durand M, Avril A and Coindre JM (1995) Prognostic value of p53 in breast invasive ductal carcinoma: an immunohistochemical study of 942 cases. Breast Cancer Res Treat 36: 71-81
30. Mantel N (1966) Evaluation of survival data and two rank order statistics arising in its consideration. Cancer Chemother Res 50: 163-170
31. Peyrat JP, Vanlemmens L, Fournier J, Huel G, Révillon F and Bonneterre J (1998) Prognostic value of p53 and urokinase-type plasminogen activator in node negative human breats cancers. Clin Cancer Res 4: 189-196
32. Pichon MF, Broët P, Magdelenat H, Delarue JC. Spyratos F, Basuyau JP, Saez S, Rallet A, Courrière R, Millon R and Asselain B (1996) Prognostic value of steroid receptors after long-term follow-up of 2257 operable breast cancer. Br J Cancer 73: 1545-1552
33. Porter-Jordan K and Lippman ME (1994) Overview of the biologic markers of breast cancer. Hematol Oncol Clin North Am 8: 73-100
34. Scarff RW and Torloni H (1968) Histological Typing of Breast Tumors, pp. 1 3-20. World Health Organization: Geneva 13-20
35. Schmitt M, Thomssen C, Ulm K, Selderer A, Harbeck N, Höfler H, Jänicke F and Graeff H (1997) Time-varying prognostic impact of tumour biological factors urokinase (uPA), PAI-1 and steroid hormone receptor status in primary breast cancer. Br J Cancer 76: 306-311
36. Sjörgren S, Iganas M, Norberg T, Lindgren A, Nordgren H, Holmberg L and Bergh J (1996) The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst 88: 173-182
37. S-Plus Version 3.2 Guide to Statistics (1993) Statistical Sciences: Seattle, WA
38. Therneau TM, Grambsch PM and Fleming TR (1990) Martingale-based residuals for survival models. Biometrika 77: 147-160
39. Thor AD and Yandell DW (1993) Prognostic significance of p53 overexpression in node-negative breast carcinomas: preliminary results support cautious optimism. J Natl Cancer Inst 85: 176-177
40. UICC (Union Internationale Contre le Cancer) (1988) TNM Classification des Tumeurs Malignes, Springer-Verlag: Paris pp. 99-106
41. Velculescu VE and El-Deiry WS (1996) Biological and clinical importance of the p53 tumor suppressor gene. Clin Chem 42: 858-868
42. Vojtesek B, Bártek J, Migdley CA and Lane DP (1992) An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. J Immuno Methods 151: 237-244